Clinical trials: Chest Pain With Normal Coronary Angiography
Microvascular Angina
Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)
The purpose of this study is to look at the effects of the drug Ranolazine compared to Placebo on symptoms of chest pain or chest tightness (known as angina), exercise endurance and ability, and changes in blood flow to the very…
- Trial name
- MARINA (NCT02147067)
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Emory University
Slow Coronary Flow, Normal, or Near Normal Coronary Angiography
Effects of Nicorandil on Angina Symptoms in Patients With Coronary Slow Flow
Slow coronary flow is an angiographically diagnosed phenomenon defined as delayed opacification of epicardial arteries in the absence of significant arterial narrowing and blockade.
- Conditions
- Slow Coronary Flow, Normal, or Near Normal Coronary Angiography, Stable Angina
- Trial name
- NCT02254252
- Testing
- Nicorandil, Nitroglycerin
- Volunteers
- 54 people
- Sponsor
- Mashhad University of Medical Sciences
Metabolic Syndrome X
Effects the Glycemic Index on Metabolic Risk Markers
Recent population studies have shown that the glycemic index (GI) of food products is positively associated with the risk of developing type 2 diabetes and cardiovascular disease (CVD).
- Trial name
- NCT00695825
- Testing
- Low GI+high GI, High GI+low GI
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Coronary Microvascular Disease
Personalized Medicine Using Coronary Microvascular Function Measured in Patient With Percutaneous Coronary Intervention in Angina
The evidence demonstrating the importance of coronary microcirculation in the management of patients with coronary artery disease is growing.
- Trial name
- DECISIONING (NCT05178914)
- Testing
- Treatment adaptation
- Where
- France
- Volunteers
- 280 people
- Sponsor
- University Hospital, Grenoble
Microvascular Angina, Vasospastic Angina
Transcutaneous Electrical Nerve Stimulation in Patients With Angina and Non-Obstructive Coronary Arteries
In patients with angina pectoris undergoing a coronary angiography (CAG) up to 40% do not have obstructive coronary artery disease (CAD).
- Trial name
- TENS-ANOCA (NCT06401291)
- Testing
- Transcutaneous Electrical Nerve Stimulation
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Prediabetic State, Obesity
Pancreatic Islet Function, Insulin Sensitivity, and Chronic Complications in Pre-Diabetes
We, the investigators at National Taiwan University Hospital, want to compare patients' islet cell function, insulin sensitivity and risk of chronic complications with normal subjects.
- Conditions
- Prediabetic State, Obesity, Metabolic Syndrome X
- Trial name
- NCT00172796
- Where
- Taiwan
- Sponsor
- National Taiwan University Hospital
Coronary Microvascular Disease, Artificial Intelligence
Artificial Intelligence With DEep Learning on COROnary Microvascular Disease
Despite the progress made in the management of myocardial infarction (MI), the associated morbidity and mortality remains high. Numerous scientific data show that damage of the coronary microcirculation (CM) during a STEMI…
- Conditions
- Coronary Microvascular Disease, Artificial Intelligence, Cardiovascular Diseases, Heart Failure
- Trial name
- AIDECORO (NCT04598997)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- University Hospital, Grenoble
Heart Failure With Preserved Ejection Fraction, Microvascular Angina
Neuregulin-1 in Patient With Different Forms of Cardiovascular Diseases: a Pilot Study
This is an observational study of Neuregulin-1 (NRG-1) plasma levels in patients with different forms of cardiovascular disease including microvascular angina (MVA), heart failure with preserved ejection fraction (HFpEF), as well…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Microvascular Angina, Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction
- Trial name
- NRG-1-CVDs (NCT04391491)
- Testing
- Neuregulin-1β level in plasma
- Where
- Russia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Non-obstructive Coronary Disease, Acute or Chronic Coronary Artery Disease
Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study
The aim of this study is to establish the diagnostic performance of the AngioAI+ System (AngioInsight, Inc, USA) for estimating: 1. Fractional flow reserve (FFR) and 2.
- Trial name
- SMARTFLOW (NCT07676097)
- Testing
- Patients with intermediate coronary artery stenosis with clinically indicated FFR assessment., Microvascular assessment
- Where
- 9 sites in United States
- Volunteers
- 620 people
- Sponsor
- AngioInsight
Coronary Artery Disease, Atherosclerosis
Biological Efficacy of Clopidogrel After Implantation of Drug-eluting Stents (SPACE)
The risk of thrombotic complications after implantation of drug-eluting stents (DES) may be increased in patients with diabetes mellitus (DM) or metabolic syndrome (MS).
- Conditions
- Coronary Artery Disease, Atherosclerosis, Diabetes Mellitus, Metabolic Syndrome X
- Trial name
- SPACE (NCT00298428)
- Testing
- blood samples
- Where
- 2 sites in France
- Volunteers
- 159 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Metabolic Syndrome X, Cardiovascular Diseases
The Effects of Beta-glucan Enriched Oatcake Consumption on Metabolic Disease Risk Factors
The purpose of this study is to determine whether daily consumption of soluble fibre, oat beta glucan (4g), for six weeks will have any impact on overweight/obese individuals in terms of risk factors used to define metabolic…
- Trial name
- NCT02615444
- Testing
- Beta-glucan enriched oatcake, Isocaloric control
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Queen Margaret University
Cardiovascular Disease, Metabolic Syndrome X
Inflammatory Profiles of Children at High Risk for Atherosclerosis
The purpose of this study is to evaluate levels of inflammatory mediators in children at risk for cardiovascular disease due to family history.
- Conditions
- Cardiovascular Disease, Metabolic Syndrome X, Hypercholesterolemia, Inflammation
- Trial name
- NCT00115232
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Boston Children's Hospital
Heart Failure, Congestive, Metabolic Syndrome X
Collaborative Care for Heart Failure Patients With the Metabolic Syndrome
Heart failure is a condition where the heart does not pump enough blood to the rest of the body. People with heart failure may have another condition called the "metabolic syndrome"( having excess fat in the belly, high blood…
- Trial name
- NCT00293852
- Testing
- Outpatient clinic follow-up
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Baylor College of Medicine
NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations
Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations
This study is a Phase 2 trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in patients with NLRC4-GOF, XIAP deficiency, or CDC42 mutations.
- Trial name
- MASter-1 (NCT04641442)
- Testing
- MAS825
- Where
- 12 sites in United States, Czechia and 5 more
- Volunteers
- 17 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Microvascular Disease
Clinical Evaluation of Aromatic Wentong in the Treatment of Coronary Microvascular Disease
Coronary Microvascular Disease (CMD) is a condition where patients experience chest pain (angina) even though their coronary arteries appear normal on angiography.
- Trial name
- NCT06901570
- Testing
- Kuangxiong Aerosol
- Where
- China
- Volunteers
- 528 people
- Sponsor
- China-Japan Friendship Hospital
Coronary Microvascular Disease
An Observational Study of Coronary Microvascular Disease of China
Non-obstructive coronary heart disease refers to patients with angina pectoris without significant narrowing of the epicardial vessels.
- Trial name
- CCMD (NCT06676137)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Henan Institute of Cardiovascular Epidemiology
Coronary Microvascular Dysfunction, Coronary Microvascular Disease
Simultaneous Assessment of Coronary Microvascular Dysfunction and Ischemia With Non-obstructed Coronary Arteries With Intracoronary Electrocardiogram and Intracoronary Doppler
Coronary Microvascular Dysfunction has been consistently shown to play a considerable role in pathophysiology of Ischaemia with non-obstructed coronary arteries (INOCA).
- Conditions
- Coronary Microvascular Dysfunction, Coronary Microvascular Disease, Non-Obstructive Coronary Atherosclerosis, Microvascular Angina
- Trial name
- NCT05471739
- Where
- Turkey (Türkiye)
- Volunteers
- 35 people
- Sponsor
- Istanbul University
Prediabetic State, Metabolic Syndrome X
Culturally-adapted Diabetes Prevention Lifestyle Intervention for Latinos (E-LITE Latinos)
The purpose of the study is to develop a culturally adapted intervention (CAI) program to improve weight and physical activity in overweight or obese adult Latinos at high risk for developing type 2 diabetes and/or cardiovascular…
- Conditions
- Prediabetic State, Metabolic Syndrome X, Insulin Resistance
- Trial name
- NCT02459691
- Testing
- Vida Sana, Usual Care Only
- Volunteers
- 191 people
- Sponsor
- Palo Alto Medical Foundation
Diabetes Mellitus, Type 2, Metabolic Syndrome X
Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness
Cilostazol is an antiplatelet agent used to reduce the symptoms of intermittent claudication. Cilostazol inhibits phosphodiesterase III (PDE III), which causes it to be a vasodilator and inhibitor of platelet aggregation.
- Trial name
- NCT00573950
- Testing
- cilostazol
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Korea University Anam Hospital
Coronary Microvascular Dysfunction, Coronary Microvascular Disease
Self-Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD) (SERRA-I Study)
VahatiCor's Coronary Sinus Reducer (A-FLUX) has been designed to improve angina or angina-like symptoms in patients with CMD. SERRA-I is an early feasibility study that evaluates the safety and clinical performance of the A-FLUX…
- Trial name
- NCT06991322
- Testing
- A-FLUX Reducer System
- Where
- 3 sites in Netherlands, Poland and 1 more
- Volunteers
- 30 people
- Sponsor
- VahatiCor, Inc.